Drugs / YL-15293
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05173805 | Jan 2022 → Apr 2024 | neoplasm | Shanghai YingLi Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05119933 | Nov 2021 → Jun 2023 | neoplasm | Shanghai YingLi Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YL-15293 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05173805 ↗ |
| Route | Oral | “receive oral YL-15293 once daily” NCT05119933 ↗ |